OBJECTIVES: Germ-line genetic variation may affect clinical outcomes of cancer patients. We applied a candidate-gene approach to evaluate the effect of putative markers on survival of patients with pancreatic cancer. We also examined gene-radiotherapy and gene-chemotherapy interactions, aiming to explain interindividual differences in treatment outcomes. METHODS: In total, 211 patients with pancreatic cancer were recruited in a population-based study. Sixty-four candidate genes associated with cancer survival or treatment response were selected from existing publications. Genotype information was obtained from a previous genome-wide association study data set. The main effects of genetic variation and gene-specific treatment interactions on overall survival were examined by proportional hazards regression models. RESULTS: Fourteen genes showed evidence of association with pancreatic cancer survival. Among these, rs1760217, located at the DPYD gene; rs17091162 at SERPINA3; and rs2231164 at ABCG2 had the lowest P of 10(-4.60), 0.0013, and 0.0023, respectively. We also observed that 2 genes, RRM1 and IQGAP2, had significant interactions with radiotherapy in association with survival, and 2 others, TYMS and MET, showed evidence of interaction with 5-fluorouracil and erlotinib, respectively. CONCLUSIONS: Our study suggested significant associations between germ-line genetic polymorphisms and overall survival in pancreatic cancer, as well as survival interactions between various genes and radiotherapy and chemotherapy.
OBJECTIVES: Germ-line genetic variation may affect clinical outcomes of cancerpatients. We applied a candidate-gene approach to evaluate the effect of putative markers on survival of patients with pancreatic cancer. We also examined gene-radiotherapy and gene-chemotherapy interactions, aiming to explain interindividual differences in treatment outcomes. METHODS: In total, 211 patients with pancreatic cancer were recruited in a population-based study. Sixty-four candidate genes associated with cancer survival or treatment response were selected from existing publications. Genotype information was obtained from a previous genome-wide association study data set. The main effects of genetic variation and gene-specific treatment interactions on overall survival were examined by proportional hazards regression models. RESULTS: Fourteen genes showed evidence of association with pancreatic cancer survival. Among these, rs1760217, located at the DPYD gene; rs17091162 at SERPINA3; and rs2231164 at ABCG2 had the lowest P of 10(-4.60), 0.0013, and 0.0023, respectively. We also observed that 2 genes, RRM1 and IQGAP2, had significant interactions with radiotherapy in association with survival, and 2 others, TYMS and MET, showed evidence of interaction with 5-fluorouracil and erlotinib, respectively. CONCLUSIONS: Our study suggested significant associations between germ-line genetic polymorphisms and overall survival in pancreatic cancer, as well as survival interactions between various genes and radiotherapy and chemotherapy.
Authors: H A Burris; M J Moore; J Andersen; M R Green; M L Rothenberg; M R Modiano; M C Cripps; R K Portenoy; A M Storniolo; P Tarassoff; R Nelson; F A Dorr; C D Stephens; D D Von Hoff Journal: J Clin Oncol Date: 1997-06 Impact factor: 44.544
Authors: Noah M Hahn; Sharon Marsh; William Fisher; Robert Langdon; Robin Zon; Mark Browning; Cynthia S Johnson; Tiffany J Scott-Horton; Lang Li; Howard L McLeod; Christopher J Sweeney Journal: Clin Cancer Res Date: 2006-10-15 Impact factor: 12.531
Authors: Donghui Li; Yanan Li; Li Jiao; David Z Chang; Garth Beinart; Robert A Wolff; Douglas B Evans; Manal M Hassan; James L Abbruzzese Journal: Int J Cancer Date: 2007-04-15 Impact factor: 7.396
Authors: M W Saif; Hany Ezzeldin; Katisha Vance; Sandra Sellers; Robert B Diasio Journal: Cancer Chemother Pharmacol Date: 2006-12-13 Impact factor: 3.333
Authors: Malcolm J Moore; David Goldstein; John Hamm; Arie Figer; Joel R Hecht; Steven Gallinger; Heather J Au; Pawel Murawa; David Walde; Robert A Wolff; Daniel Campos; Robert Lim; Keyue Ding; Gary Clark; Theodora Voskoglou-Nomikos; Mieke Ptasynski; Wendy Parulekar Journal: J Clin Oncol Date: 2007-04-23 Impact factor: 44.544
Authors: Judith A Gilbert; Oreste E Salavaggione; Yuan Ji; Linda L Pelleymounter; Bruce W Eckloff; Eric D Wieben; Matthew M Ames; Richard M Weinshilboum Journal: Clin Cancer Res Date: 2006-03-15 Impact factor: 12.531
Authors: Donghui Li; Marsha Frazier; Douglas B Evans; Kenneth R Hess; Christopher H Crane; Li Jiao; James L Abbruzzese Journal: J Clin Oncol Date: 2006-03-06 Impact factor: 44.544
Authors: A Sultana; C Tudur Smith; D Cunningham; N Starling; D Tait; J P Neoptolemos; P Ghaneh Journal: Br J Cancer Date: 2007-04-03 Impact factor: 7.640
Authors: Kristen S Hill; Ivana Gaziova; Lindsay Harrigal; Yvette A Guerra; Suimin Qiu; Sarita K Sastry; Thiruvengadam Arumugam; Craig D Logsdon; Lisa A Elferink Journal: PLoS One Date: 2012-07-17 Impact factor: 3.240